Revolutionizing Echocardiography: Visura Technologies Launches TEECAD Mini for Adult Patients

Visura Technologies, a leading medical device company based in Minneapolis, has announced the launch of its latest innovation in transesophageal echocardiography (TEE) imaging technology – the TEECAD mini. This new product aims to address the needs of adult patients whose anatomical requirements are not met by standard TEE probe sizes. The TEECAD mini will be showcased at the upcoming American Society of Echocardiography (ASE) 2024 conference, where Visura plans to gather feedback from key opinion leaders and demonstrate the benefits of this cutting-edge technology.

Visura’s success with its FDA-cleared TEECAD System has led to an 85% increase in evaluations at prominent medical centers and expansion of its clinical and commercialization teams. Dr. David Marmor, founder and chief medical officer of Visura, highlighted the lack of significant advancements in TEE probe technology since the 1970s and emphasized the groundbreaking progress offered by TEECAD. Clinical data presented by Dr. Sunil Mankad at last year’s ASE meeting demonstrated the safety and effectiveness of TEECAD in esophageal imaging, resulting in reduced probe placement time and increased success in first-pass intubation without any adverse events.

Visura remains committed to innovation and continues to expand its product portfolio to meet market demands and enhance patient care. This launch represents a significant milestone for Visura as it continues to push boundaries in the field of medical technology.